The QALY and Cancer Treatments: An Ill-Advised Match

Share on Facebook
Share on Twitter
Share on
LinkedIn
+

This report examines the alarming methodological and contextual shortcomings of the Quality Adjusted Life Years (QALY)-based methodology in evaluating new cancer therapies. It reveals five specific problems with ICER’s evaluation of cancer treatments and demonstrates the urgent need to prohibit the use of the QALY amid trends in rapid cancer innovations and personalized medicine.

Download: The QALY and Cancer Treatments: An Ill-Advised Match